Patents by Inventor Michael Stefanidakis

Michael Stefanidakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating CEP290 associated disease
    Patent number: 11566263
    Abstract: Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs. The nucleic acids and vectors, and compositions that comprise them, can be used in methods to treat subjects, to alter cells in subjects who may suffer from an inherited retinal dystrophy such as CEP290 associated disease or who may be in need of alteration of a cell or a cellular nucleic acid sequence associated with an inherited retinal dystrophy such as the CEP290 gene, and/or to treat inherited retinal dystrophies including CEP290 associated disease.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 31, 2023
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, Michael Stefanidakis
  • Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
    Patent number: 11524998
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: December 13, 2022
    Assignee: NOVARTIS AG
    Inventors: Chad Eric Bigelow, Ana Maria Carrion, James Edgar Chastain, Kirk Lee Clark, Bijan Alexandre Etemad-Gilbertson, Joy Gispati Ghosh, Shawn Michael Hanks, Nicole Haubst, Ganesh Rajan Iyer, Nina Moker, Andrew Anh Nguyen, Stephen Hedrick Poor, Yubin Qiu, Nalini Velamur Rangaswamy, Michael Stefanidakis, Engin Toksoz, Michael Zbigniew Twarog
  • Compositions and methods for treating CEP290-associated disease
    Patent number: 11339437
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 24, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Compositions and methods for treating CEP290-associated disease
    Patent number: 11141493
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 12, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Nucleic acids encoding anti-Factor P antibodies
    Patent number: 10865237
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 15, 2020
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • Compositions comprising antibodies targeting factor P
    Patent number: 9988440
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
    Publication number: 20150158936
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Application
    Filed: June 19, 2014
    Publication date: June 11, 2015
    Applicant: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester KUNZ, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • Antibodies that bind factor P
    Patent number: 9051365
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Sha-Mei Liao, Michael Stefanidakis
  • Inhibitors of cell migration
    Publication number: 20070099839
    Abstract: The present invention concerns peptide compounds, which were found to bind to the ?M integrin I-domain and inhibit its complex formation with proMMP-9, thereby preventing neutrophil migration. The compounds comprise the hexapeptide motif HFDDDE. The compounds can be used in prophylaxis and treatment of inflammatory conditions.
    Type: Application
    Filed: June 21, 2004
    Publication date: May 3, 2007
    Applicant: CIT CANCER TARGETING TECHNOLOGIES
    Inventors: Michael Stefanidakis, Erkki Koivunen